Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna-Sophie Thein

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Heart Rhythm|July 27, 2025
Relationship between cardiac implantable electronic devices and tricuspid regurgitation in the general populationHilary C Bowman, Janet J Tang, Anna-Sophie Thein, et al.
JAMA Network Open|August 7, 2025
Left Bundle Branch Block as a Risk Factor for Heart FailureAnna-Sophie Thein, Shalini Dixit, Elsayed Z Soliman, et al.
Frontiers in Neuroscience|March 10, 2022
Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, et al.
Ophthalmology|March 15, 2024
Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 DiabetesSiar Niazi, Filip Gnesin, Anna-Sophie Thein, et al.
American Journal of Ophthalmology|May 20, 2022
Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus StatementAnna-Sophie Thein, Anne Hedengran, Augusto Azuara-Blanco, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Heart Rhythm|July 27, 2025
Relationship between cardiac implantable electronic devices and tricuspid regurgitation in the general populationHilary C Bowman, Janet J Tang, Anna-Sophie Thein, et al.
JAMA Network Open|August 7, 2025
Left Bundle Branch Block as a Risk Factor for Heart FailureAnna-Sophie Thein, Shalini Dixit, Elsayed Z Soliman, et al.
Frontiers in Neuroscience|March 10, 2022
Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, et al.
Ophthalmology|March 15, 2024
Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 DiabetesSiar Niazi, Filip Gnesin, Anna-Sophie Thein, et al.
American Journal of Ophthalmology|May 20, 2022
Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus StatementAnna-Sophie Thein, Anne Hedengran, Augusto Azuara-Blanco, et al.
Pageof 1